Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-15 12:21 pm Purchase | 2026-03-31 | 13G | REVIVA PHARMACEUTICALS HLDGS C RVPH | CVI Investments, Inc. | 672,811 4.900% | 6,144 (+0.92%) | Filing History |
| 2026-05-14 9:25 pm Purchase | 2026-03-31 | 13G | REVIVA PHARMACEUTICALS HLDGS C RVPH | Barclays PLC | 763,579 5.960% | 763,579 (New Position) | Filing History |
| 2026-05-07 12:56 pm Purchase | 2026-03-31 | 13G | REVIVA PHARMACEUTICALS HLDGS C RVPH | UBS Group AG | 746,095 5.800% | 746,095 (New Position) | Filing History |
| 2026-03-30 5:34 pm Purchase | 2026-03-23 | 13G | REVIVA PHARMACEUTICALS HLDGS C RVPH | Integrated Core Strategies (US) LLC | 793,952 6.200% | 631,068 (+387.43%) | Filing History |
| 2026-03-25 2:28 pm Purchase | 2026-03-18 | 13G | REVIVA PHARMACEUTICALS HLDGS C RVPH | CVI Investments, Inc. | 666,667 5.200% | 488,087 (+273.32%) | Filing History |
| 2026-03-24 4:15 pm Purchase | 2026-03-20 | 13D | REVIVA PHARMACEUTICALS HLDGS C RVPH | Parag Saxena | 363,280 2.800% | 49,880 (+15.92%) | Filing History |
| 2026-02-17 4:19 pm Sale | 2025-12-31 | 13G | REVIVA PHARMACEUTICALS HLDGS C RVPH | 683 Capital Management, LLC | 174,625 3.000% | -97,125 (-35.74%) | Filing History |
| 2026-01-16 4:52 pm Purchase | 2025-12-31 | 13G | REVIVA PHARMACEUTICALS HLDGS C RVPH | Integrated Core Strategies (US) LLC | 162,884 2.800% | 84,704 (+108.34%) | Filing History |
| 2025-12-22 4:30 pm Purchase | 2025-12-18 | 13D | REVIVA PHARMACEUTICALS HLDGS C RVPH | Parag Saxena | 313,400 5.200% | 410 (+0.13%) | Filing History |
| 2025-09-29 6:59 pm Purchase | 2025-09-22 | 13G | REVIVA PHARMACEUTICALS HLDGS C RVPH | 683 Capital Management, LLC | 271,750 5.360% | 271,750 (New Position) | Filing History |
| 2025-09-24 4:33 pm Purchase | 2025-09-22 | 13D | REVIVA PHARMACEUTICALS HLDGS C RVPH | Bhat Laxminarayan | 184,044 3.800% | 3,425 (+1.90%) | Filing History |
| 2025-09-24 4:30 pm Unchanged | 2025-09-22 | 13D | REVIVA PHARMACEUTICALS HLDGS C RVPH | Parag Saxena | 312,990 6.200% | 0 (Unchanged) | Filing History |
| 2025-08-14 4:15 pm Sale | 2025-06-30 | 13G | REVIVA PHARMACEUTICALS HLDGS C RVPH | TANG CAPITAL MANAGEMENT LLC | 169,999 4.800% | -25,516 (-13.05%) | Filing History |
| 2025-08-14 4:08 pm Purchase | 2025-06-30 | 13G | REVIVA PHARMACEUTICALS HLDGS C RVPH | Highbridge Capital Management, LLC | 400,000 9.900% | 400,000 (New Position) | Filing History |
| 2025-08-14 2:01 pm Sale | 2025-06-30 | 13G | REVIVA PHARMACEUTICALS HLDGS C RVPH | CVI Investments, Inc. | 178,580 4.900% | -21,420 (-10.71%) | Filing History |
| 2025-07-01 6:40 pm Sale | 2025-06-27 | 13D | REVIVA PHARMACEUTICALS HLDGS C RVPH | Parag Saxena | 312,990 8.700% | -455 (-0.15%) | Filing History |
| 2025-07-01 4:30 pm Purchase | 2025-06-27 | 13D | REVIVA PHARMACEUTICALS HLDGS C RVPH | Bhat Laxminarayan | 180,619 5.200% | 20,707 (+12.95%) | Filing History |
| 2025-07-01 10:18 am Purchase | 2025-06-26 | 13G | REVIVA PHARMACEUTICALS HLDGS C RVPH | CVI Investments, Inc. | 200,000 5.900% | 77,681 (+63.51%) | Filing History |
| 2025-05-15 4:15 pm Purchase | 2025-03-31 | 13G | REVIVA PHARMACEUTICALS HLDGS C RVPH | TANG CAPITAL MANAGEMENT LLC | 195,515 7.800% | 195,515 (New Position) | Filing History |
| 2025-02-14 4:16 pm Sale | 2024-12-31 | 13G | REVIVA PHARMACEUTICALS HLDGS C RVPH | Schonfeld Strategic Advisors LLC | 65,746 2.820% | -22,890 (-25.82%) | Filing History |